Cancer medicines

Olaparib

Olaparib

An oral PARP inhibitor used under specific genetic and treatment conditions.

Sources checked · Introductory guide

On this page

How it works

It inhibits PARP, an enzyme involved in DNA repair.[1]

Where it is used

Used in selected ovarian, breast, pancreatic and prostate cancers after reviewing genetic results and prior therapy.[1]

Key safety points

Regular blood counts and interaction checks are needed. Report severe fatigue, fever or new breathing difficulty immediately.[2]

Questions for your care team

  • Which test results and treatment responses support choosing this drug?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Olaparib (opens in a new tab)
  2. MedlinePlus · Olaparib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

Olaparib | Cancer Encyclopedia | My Chemo Diary